fda compounding semaglutide enforcement october 2025 GLP-1 Medications – Guidance and Compounded Products FDA is moving to restrict
Description
Theres no strong evidence that timing makes a meaningful difference in how GLP-1 probiotics affect appetite or weight
The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, which narrowed but did not close the legitimate compounding window
Abstract BACKGROUND AND AIMS Heart failure with preserved ejection fraction (HFpEF) remains a therapeutic challenge
Historically, compounded drugs have often represented a solution in filling an otherwise unmet need for individual patients
Tranont Activate sits squarely in that category
When activated, they slow down intestinal movement, delay stomach emptying, and alter the migrating motor complex
